Ultragenyx Wins Big in Blood Sugar Study
Ultragenyx Pharma shares made a handy gain to close out the week after the company announced positive results from its midstage trial for the treatment of glycogen storage disease type Ia.
Ultragenyx Pharma shares made a handy gain to close out the week after the company announced positive results from its midstage trial for the treatment of glycogen storage disease type Ia.
A prominent health care analyst has identified his top health care stock picks for 2019, and some are somewhat speculative.
The U.S. crude oil inventory remained virtually unchanged week over week for the week ended on December 28. Crude prices have been rising on reports of fresh trade talks between the United States and…
Selecta Biosciences shares pushed higher on Friday after the company provided an update on its new streamlined structure under its new president and CEO.
U.S. natural gas inventories dropped by much less than expected last week and prices that have moved lower over the past two weeks lost a bit of their early-morning gains.
Did they warn their clients that Apple was about to plunge?
Investment in cannabis-related companies rose nearly fourfold year over year in 2018. Can 2019 maintain that pace?
The top analyst upgrades, downgrades and initiations seen on Friday included Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix, Nokia, Snap, United Technologies and Vonage.
Epizyme shares jumped on Friday after the company announced a set of pipeline updates as well as a key update from the FDA.
There is some great news in the U.S. Department of Labor's December jobs report, but it also comes with a catch.
Novavax shares jumped early on Friday after the company reported that its midstage flu vaccine had some positive results.
New car sales in December were disappointingly lower for two of the U.S. Detroit Three automakers as were full-year sales. Yet analysts have set high price targets for the automakers. Is that realistic?
Not that it matters (unless you have to sell).
From Jay Greene and Yoko Kubota's post-mortem in Friday's Wall Street Journal ($).
Investors with a long-term view, those that can look past the recent volatility, can own these four stocks at very good entry points, given the recent selling. Plus with limited or no exposure to…